Announcements Trials
Browse Landscape

Phase

Phase 2 82Phase 3 27Phase 1 23Phase 1/2 19Phase NA 4Phase 2/3 4Phase EARLY_PHASE1 2

Status

Withdrawn 1Enrolling by invitation 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 4Gynecologic 4CNS 3Breast 3Genitourinary 2Gastrointestinal 2Sarcoma 1Lymphoid 1Head & Neck 1

Conditions

Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Muscle Invasive Bladder Urothelial Carcinoma 1Breast Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 13gallium 68 PSMA-11 8Fluorodeoxyglucose F18 5Specimen Handling 4Positron Emission Tomography Computed Tomography 42-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 4enzalutamide 3Nivolumab 3Ipilimumab 3Interleukin-2 3Biopsy 368Ga-DKFZ-PSMA-11 3pembrolizumab 2pazopanib 2lenvatinib 2bicalutamide 2atezolizumab 2aldesleukin 2acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 2X-Rays 2Standard of Care 2Radiation 2Positron-Emission Tomography 2Paclitaxel 2Oncolytic Virotherapy 2Nephrectomy 2Metformin 2Metastasectomy 2Immunoglobulin G 2Hydroxychloroquine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Carboplatin × Genitourinary × Clear all
NCT06204614 2026-05-18

Drug Screening Using IMD in Bladder Cancer

Brigham and Women's Hospital

Phase EARLY_PHASE1 Enrolling by invitation
18 enrolled
Genitourinary

Muscle Invasive Bladder Urothelial Carcinoma

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

OHSU Knight Cancer Institute

Phase EARLY_PHASE1 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡